The role of IFN-γ and of the JAK/STAT pathway demonstrated here in vitro hints for a therapeutic potential of JAK inhibitors to treat ROSAH patients, and potentially the deleterious oncogenic ALPK1/TIFA-dependent inflammation.6 The gene discussed is ALPK1; the disease is retinal dystrophy, optic nerve edema, splenomegaly, anhidrosis, and migraine headache syndrome.